QUIDELORTHO CORP Accounts Receivable, Allowance for Credit Loss, Current
QUIDELORTHO CORP (QDEL) had Accounts Receivable, Allowance for Credit Loss, Current of $15.20 million as of 2026-06-28, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Assets, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent · last filed 2026-08-07
- 2026-06-28: Accounts Receivable, Allowance for Credit Loss, Current $15.20M.
- 2026-03-29: Accounts Receivable, Allowance for Credit Loss, Current $16.70M.
- 2025-12-28: Accounts Receivable, Allowance for Credit Loss, Current $17.30M.
- 2025-09-28: Accounts Receivable, Allowance for Credit Loss, Current $17.70M.
| Period end | Accounts Receivable, Allowance for Credit Loss, Current |
|---|---|
| 2026-06-28 | $15.20M 10-Q · filed 2026-08-07 |
| 2026-03-29 | $16.70M 10-Q · filed 2026-05-06 |
| 2025-12-28 | $17.30M 10-Q · filed 2026-08-07 |
| 2025-09-28 | $17.70M 10-Q · filed 2025-11-06 |
| 2025-06-29 | $15.90M 10-Q · filed 2025-08-06 |
| 2025-03-30 | $14.70M 10-Q · filed 2025-05-08 |
| 2024-12-29 | $14.30M 10-Q · filed 2025-11-06 |
| 2024-09-29 | $13.70M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $13.80M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $15.20M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $14.60M 10-Q · filed 2024-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |